Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Novel PCR reaction bead extends global reach of active TB test by removing the cold chain

Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR reaction bead for its Actiphage® blood test for active TB. This enables ambient shipping without the need for a cold chain, which reduces the cost of shipment and extends the shelf-life for components of the test.
  • March 17, 2023
  • Human health, Latest, Press release
PCR bead

Products that contain enzymes are temperature-sensitive and require cold chain transport to ensure their functional integrity. Lyophilization is a water removal process that can be used to extend shelf-life.

Joely Irlam, Chief Technology Officer for PBD Biotech, explains: “Although lyophilized products for drugs and food aren’t unusual, using this technology for a PCR product is novel. It is expensive and time consuming to re-develop the product in a lyophilised format and to ensure that sensitivity and specificity aren’t compromised.”

“PBD has addressed this pain early doors to ensure the product aligns with the WHO Target Product Profile (TPP) and allows an extension of shelf-life, which is always good for the customer.”

PBD has developed PCR primers and probes that allow specific detection of DNA lysed from Mycobacteria tuberculosis (Mtb) isolated from a human whole blood sample. The beads will contain polymerase enzyme, UNG enzyme to prevent contamination, dNTPs, oligonucleotide primers and probes and PCR additives.

Joely continues: “The PCR has also been specially developed to target multiple sites within the relevant insertion elements in the MTBC rather than just one. This is a unique feature and improves the test’s ability to detect Mtb at levels much lower than previously achieved.

“The new bead offers easy ambient shipping. Cold chain transport can limit the distance and/or time a sample can be in transit without guaranteed replenishment, so the bead will extend the global reach of Actiphage.”

By enabling early detection of TB disease progression, Actiphage has the potential to break the cycle of infection – offering an exciting contribution to the WHO #EndTB initiative.

Jane Theaker, CEO of PBD Biotech, says that the early testing and treatment of patients who have the infection and are likely to progress to active disease before they pass on their infection is an important pillar of the #EndTB campaign, but there are other areas where Actiphage can also provide support.

She says: “Actiphage could also be used to enable the stratification of patients for new TB drugs and vaccine therapies in clinical trials. In this way, the effectiveness of treatments can be assessed much more efficiently, leading to improved targeted drugs and vaccines.

“Antimicrobial resistance is a growing concern for the treatment of TB. Actiphage could be used to monitor the effectiveness of drug treatments, ensuring that, once the infection is cleared from the blood, the drug treatment can be stopped. In this way the potential for antimicrobial resistance can be minimised. This safeguards drug treatments for future use in TB patients.”

Share:

Related posts

Loading...
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic...
AACC webinar phage-based TB diagnostics

19 April 2023

‘We can #EndTB’ – phage-based diagnostics for TB to be discussed at AACC webinar

March 22, 2023
The role of phage-based laboratory diagnostics in the detection of tuberculosis is to be discussed in a live webinar hosted by the AACC, it has been announced ahead of World TB Day.
AACC webinar phage-based TB diagnostics

19 April 2023

‘We can #EndTB’ – phage-based diagnostics for TB to be discussed at AACC webinar

March 22, 2023
The role of phage-based laboratory diagnostics in the detection of tuberculosis is to be discussed in a live webinar hosted...

Actiphage TB test patent extended to West Africa

February 24, 2023
PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual Property Organization (OAPI). This covers the mainly French-speaking countries of West Africa.

Actiphage TB test patent extended to West Africa

February 24, 2023
PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
1 2 … 7 Next »

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!